Drugs / BMS-986263
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04225936 | Jan 2020 → Jun 2021 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03142165 | May → Nov 2017 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT04267393 | Mar 2021 → Aug 2023 | metabolic dysfunction-associated steatohepatitis | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 2 | NCT03420768 | Feb → Dec 2018 | cirrhosis of liver, fibrotic liver disease | Bristol-Myers Squibb | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986263 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04225936 ↗ |
| Action | Inhibit | “designed to degrade HSP47 mRNA” PMID 34605045 ↗ Dec 2021 |
| Modality | Small interfering RNA (siRNA) | “a lipid nanoparticle delivering small interfering RNA designed to degrade HSP47 mRNA” PMID 34605045 ↗ Dec 2021 |
| Route | Intravenous | “infused intravenous administration” NCT03142165 ↗ |